[usPropHeader] Error loading user control: The file '/CMSWebParts/WK.HLRP/LNC/LNCProductHeader.ascx' does not exist.

Authors

  1. Dalal, Kavitha S. PharmD
  2. Bridgeman, Mary Barna PharmD, BCPS

Article Content

Can you identify these combination cardiovascular drugs? To find out, match each brand name in Section I with its generic name in Section II.

 

Section I

______ 1. Byvalson (Allergan USA)

 

______ 2. Yosprala (Aralez Pharmaceuticals U.S.)

 

______ 3. Entresto (Novartis)

 

______ 4. Prestalia (Symplmed)

 

Section II

a. sacubitril and valsartan. These film-coated tablets combine an angiotensin II receptor blocker (ARB) and a neprilysin inhibitor. This drug is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

 

b. perindopril and amlodipine. Indicated to manage hypertension, this drug combines an angiotensin-converting enzyme inhibitor and a dihydropyridine calcium channel blocker. This drug isn't recommended for use in patients with severe renal impairment.

 

c. nebivolol and valsartan. This drug, indicated to treat hypertension, is a combination of a beta-1 selective beta-blocker and an ARB. It can be administered with or without food. Warn patients not to discontinue the drug abruptly. In general, patients with bronchospastic disorders should avoid beta-blockers.

 

d. aspirin and omeprazole. Combining an antiplatelet agent and a proton pump inhibitor, this drug is indicated to reduce the risk of aspirin-associated gastric ulcers in at-risk patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events. Teach patients to take each daily dose at least 1 hour before a meal, and warn them not to split, chew, crush, or dissolve the tablets.

 

Resources available upon request.

 

ANSWERS: 1c, 2d, 3a, 4b